A device for producing radiopharmaceuticals used in cancer diagnosis and treatment
Official title: Single-use Microfluidic Device for Radiopharmaceutical Production
Funded at University of Tx Md Anderson Can Ctr · NIH-11130091 · Data updated 2026-11-12
This study is working on a new, easy-to-use device that helps make special medicines for cancer diagnosis and treatment faster and cheaper, so more patients can get the tests they need to find and understand their tumors better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $574,632 |
| NIH project number | 1R01EB034665-01A1 |
| Project ID | NIH-11130091 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with solid tumors, including breast, pancreatic, and lung cancers, who may benefit from advanced imaging and targeted therapies.
✕Less likely to help
Patients with cancers that do not utilize radiopharmaceuticals for diagnosis or treatment may not receive benefits from this research.
What this research studies
This research focuses on developing a single-use microfluidic device that simplifies the production of radiopharmaceuticals, which are crucial for cancer diagnosis and therapy. By utilizing this innovative technology, the goal is to make the production process faster and more cost-effective, thereby increasing access to these essential diagnostic tools. The device aims to enhance the ability to detect tumors and assess their characteristics through advanced imaging techniques like positron emission tomography (PET). Patients may benefit from improved diagnostic accuracy and more personalized treatment options as a result of this research.
Why it matters
Potential benefit: If successful, this research could lead to more accessible and efficient cancer diagnostics and treatments for patients.
How similar studies have gone: Previous research has shown success in using microfluidic technologies for various applications, indicating potential for this novel approach in radiopharmaceutical production.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Manning, Henry Charles — University of Tx Md Anderson Can Ctr
- Study coordinator: Manning, Henry Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.